Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-06-04

FDA Approved: VYONDYS 53 — Supplemental Application (Sarepta Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VYONDYS 53 (golodirsen) filed by Sarepta Therapeutics, expanding regulatory status for Duchenne muscular dystrop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VYONDYS 53 (golodirsen)

Snippet

SUPPL AP for VYONDYS 53 (GOLODIRSEN)